ArticleBMC pediatrics2025
Treatment of a case with short stature and Goltz syndrome with long-acting growth hormone: a case report and follow-up.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Goltz syndrome, also known as focal dermal hypoplasia, is an X-linked dominant genetic disorder caused by mutations in the PORCN gene, mainly characterized by developmental impairments affecting the skin, hair, bones, teeth, and eyes. This study reports a case with extensive skin dysplasia, limb malformations, and short stature. The genomic DNA whole exome sequencing of the child at 1 month of age revealed a mutation in the PORCN gene, confirming the diagnosis of Goltz syndrome. When she was 3 years old, she suffered from weight loss (W<-3SD) and was short for her age (H<-3SD). The growth hormone stimulation test confirmed growth hormone deficiency. She was treated with long-acting growth hormone (0.2 mg/Kg/week) for 2 years and 9 months, leading to a significant increase in height, with an average annual growth rate of 9.4 cm, without any side effects after three years of follow-up. Goltz syndrome with short stature may be associated with growth hormone deficiency, and long-term growth hormone therapy can achieve clinical benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.